Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations

Cheng Y.Murakami HPAN-CHYR YANGHe JNakagawa KKang J.HKim J.-HWang XEnatsu SPuri TOrlando MCHIH-HSIN YANG2020-05-262020-05-2620160732-183Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84989899472&doi=10.1200%2fJCO.2016.66.9218&partnerID=40&md5=91e5c828918d25a2dd7ae6f808db254chttps://scholars.lib.ntu.edu.tw/handle/123456789/494973[SDGs]SDG3Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutationsjournal article10.1200/JCO.2016.66.9218275078762-s2.0-84989899472